文献速递神经免疫认知障碍与痴呆

儿童多发性硬化与抗体相关脱髓鞘:诊断与照护的临床、影像和生物学考量

Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care.
PubMed 文献 · Lancet Neurol · 2021-01-20

本文综述儿童获得性中枢神经系统神经免疫脱髓鞘领域的转变,指出多发性硬化、MOG抗体相关疾病和AQP4抗体相关视神经脊髓炎谱系疾病现可基于人类和动物模型证据区分,各自具有不同病理机制。成人高效疗法(复发率降低超90%)推动儿童试验,但疾病罕见需新试验设计如基于成人三期研究的年龄轨迹建模。

要点

  • 儿童神经免疫脱髓鞘现可区分MS、MOGAD和AQP4-NMOSD三种疾病。
  • 成人高效疗法降低复发率超90%,推动儿童临床试验。
  • 儿童疾病罕见,需年龄轨迹建模等新试验设计方法。

核心结论

  • 儿童MS、MOGAD和AQP4-NMOSD可基于不同病理机制区分,未来治疗前景更光明。

研究设计与样本

  • 综述性文章,未报告系统检索范围或样本量。

主要发现

  • 三种神经免疫疾病可通过人类和动物模型证据区分,支持不同病理机制。
  • 成人MS和AQP4-NMOSD高效疗法使复发率降低超90%。

关键数值与推荐

  • 成人高效疗法降低复发率超过90%。

临床怎么用

  • 临床可区分儿童MS、MOGAD和AQP4-NMOSD以指导诊断和照护。
  • 儿童临床试验可借鉴成人三期研究的年龄轨迹建模方法。

局限性

  • 儿童疾病罕见,临床试验具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The field of acquired CNS neuroimmune demyelination in children is transforming. Progress in assay development, refinement of diagnostic criteria, increased biological insights provided by advanced neuroimaging techniques, and high-level evidence for the therapeutic efficacy of biological agents are redefining diagnosis and care. Three distinct neuroimmune conditions-multiple sclerosis, myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (AQP4-NMOSD)-can now be distinguished, with evidence from humans and animal models supporting distinct pathobiological disease mechanisms. The development of highly effective therapies for adult-onset multiple sclerosis and AQP4-NMOSD that suppress relapse rate by more than 90% has motivated advocacy for trials in children. However, doing clinical trials is challenging because of the rarity of these conditions in the paediatric age group, necessitating new approaches to trial design, including age-based trajectory modelling based on phase 3 studies in adults. Despite these limitations, the future for children and adolescents living with multiple sclerosis, MOGAD, or AQP4-NMOSD is far brighter than in years past, and will be brighter still if successful therapies to promote remyelination, enhance neuroprotection, and remediate cognitive deficits can be further accelerated.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Fadda G, Armangue T, Hacohen Y, et al. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 2021. PMID: 33484648. doi:10.1016/S1474-4422(20)30432-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。